Commentary
In this review, L. J. M. Heyens et al. (Hasselt University, Belgium, Maastricht University, Netherlands, and, Ziekenhuis Oost-Limburg, Belgium) give an overview of the pathogenic mechanisms of the evolution from isolated steatosis to fibrosis. The authors also discuss of the current and future diagnostic biomarkers and anti-fibrotic drugs.
Previous Post
Increased portal pressure in non-cirrhotic NAFLD: a review
Next Post
Mediterranean dietary pattern and non-alcoholic fatty liver diseases: a case-control study